Trial · NCT07183319
Circulating Tumor DNA Response In Urothelial Cancer
NCT07183319, Phase 2, Recruiting, University of Oklahoma
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Circulating Tumor DNA Response In Urothelial Cancer. Trials, record NCT07183319. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07183319
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Circulating Tumor DNA Response In Urothelial Cancer
- NCT number
- NCT07183319
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 30 participants, estimated
- Lead sponsor
- University of Oklahoma
- Conditions
- Urothelial Carcinoma
- Interventions
- Pembrolizumab & Enfortumab Vedotin (PEV), Pembrolizumab, Pembrolizumab & Enfortumab Vedotin (PEV)
- First posted
- 2025-09-19
- Last updated
- 2026-02-02
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 3 months of progression-free survival (PFS) while on Pembrolizumab Monotherapy. | 3 months | Number of patients who achieve PFS at the 3-month mark on pembrolizumab monotherapy. These patients will undergo radiographic assessments to evaluate progression-free survival (PFS). |
| Primary | 6 months of PFS while on Pembrolizumab Monotherapy | 6 months | Number of patients in the de-escalation phase who have reached 6-month PFS while on pembrolizumab monotherapy. |
| Secondary | Treatment Related Adverse Events (TRAEs) while on Pembrolizumab Monotherapy. | 1 year | Number of patients who experience treatment-related adverse events (TRAEs) while in the de-escalation phase treated with pembrolizumab monotherapy following 1L PEV. Any adverse events (AEs) or TRAEs that do occur will be assessed and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. |
| Secondary | Pain Assessment In Patients While On Pembrolizumab Monotherapy. | 1 year | The Brief Pain Inventory (BPI) questionnaire will be administered to assess participants' perceived pain levels. Pain intensity will be rated on a Likert scale ranging from 0, indicating no pain, to 10, representing the most severe and unimaginable pain. |
| Secondary | Changes In Peripheral Neuropathy While on Pembrolizumab Monotherapy | 1 year | The Functional Assessment of Cancer Therapy-Neurotoxicity 12 (FACT-NTX-12) will be administered every 12 weeks to evaluate peripheral neuropathy. This tool measures quality of life in relation to neuropathy symptoms, vibration perception threshold, and extension strength testing. Responses are rated on a 5-point Likert scale, ranging from 0 ("not at all") to 4 ("very much"). |
| Secondary | Health Assessment In Patients While On Pembrolizumab Monotherapy | 1 year | The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) will be administered to assess participants' quality of life, including physical, emotional, and social functioning, as well as cancer-related symptoms. Responses are measured on a Likert scale from 1 ("not at all") to 4 ("very much"). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07183319
GET https://conductscience.org/api/trials/v1/NCT07183319/registered